Business
Formation of OptiBiotix Health India
Formation of OptiBiotix Health India.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5834S\n OptiBiotix Health PLC\n 17 November 2021\n \n \n \n OptiBiotix Health plc\n (\"OptiBiotix\" or the \"Company\" or the \"Group\")\n \n Formation of OptiBiotix Health India\n \n \n OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds that modulate the microbiome to tackle metabolic syndrome, systemic low grade inflammation, obesity and diabetes, cardiovascular disease and high cholesterol, announces the formation of its new Indian subsidiary, OptiBiotix Health India Ltd (\"OHI\").\n \n \n \n With a population of 1.3 billion people and cardiovascular disease accounting for up to 27% of all deaths (WHO) and obesity prevalence at 40.3% (https://journals.sagepub.com/doi/full/10.1177/0972753120987465), India is a market of great strategic importance to OptiBiotix. The formation of OHI allows significant opportunities for additional revenue growth through sales of the Group's products in India. The middle-class population in India is expected to reach 475 million by 2030. Currently most middle-class consumers live in the European Union (EU) and the United States, but over the next decade, the majority will shift heavily toward India, with one in four global middle-class consumers expected to reside in India by 2035 https://www.asianstudies.org/publications/eaa/archives/the-middle-class-in-india-from-1947-to-the-present-and-beyond/. \n The nutraceuticals market in India is expected to grow from $4 billion in 2017 to $18 billion in 2025 against the backdrop of rising demand for dietary supplements from upper and middle class https://www.investindia.gov.in/team-india-blogs/growing-nutraceuticals-market-india.\n In March 2021, OptiBiotix announced the appointment of Dr Taru Jain to focus on business development and growing sales in the strategically important Indian and Asian markets. The formation of OHI builds on that presence and is expected to bring the following benefits:-\n \n \n · \n OHI will be able to manage the purchase and sale of ingredients (e.g. LPLDL\n ®,\n SlimBiome\n ®\n ) and final product (e.g. CholBiome\n ®\n range, GoFigure\n ®\n ) manufactured and sold in India increasing operational efficiency and partner engagement. This is highly challenging without a physical presence in India\n \n \n · \n OHI wil...